No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 39 of the 40 quarters in the window, leaving 1 comparable quarter; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Mustang Bio, Inc. (MBIO) stock was $0.46 as of Oct 6, 2026, 10:58 AM EDT, up 0.24% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -70.7% · 3-year avg -83.4%/yr · 5-year avg -80.8%/yr
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
Biotechnology · Waltham, MA
Next Earnings Date
Nov 18, 2026
43 days away
EPS Estimate
-140.00
Revenue Est.
N/A
Last Quarter Results
EPS
$3.63
vs Estimate
$-8.00
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MBIO | $3.49M | $0.46 | +0.24% | -70.71% | -80.80% | N/A | N/A |
| 2MLEC | $3.51M | $4.84 | -0.41% | -64.99% | -68.13% | N/A | vs MBIO |
| 3NXL | $3.57M | $4.87 | -10.31% | -79.96% | N/A | N/A | vs MBIO |
| 4EVGN | $3.40M | $0.40 | -2.18% | -64.71% | -56.46% | -39.70% | vs MBIO |
| 5EOCN | $3.36M | $3.23 | -6.39% | N/A | N/A | N/A | vs MBIO |
| 6ICCM | $3.33M | $1.48 | -3.90% | -94.60% | -63.05% | N/A | vs MBIO |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$0.46
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-140.00 | $-140.00 | $-140.00 | 1 |
| Quarter ending Dec 2026 | $-145.50 | $-145.50 | $-145.50 | 1 |
| Quarter ending Mar 2027 | $-135.19 | $-135.19 | $-135.19 | 1 |
| Quarter ending Jun 2027 | $-144.00 | $-144.00 | $-144.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-99.00 | $-99.00 | $-99.00 | 1 |
| FY 2027 | $-51.50 | $-51.50 | $-51.50 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $11.00M | $11.00M | $11.00M | 1 |
| FY 2027 | $55.60M | $55.60M | $55.60M | 1 |
